Full Breakdown
Novo Rebrands as “Novo” in Bid to Reclaim Obesity-Drug Market
By Drooid · · How we work
Core Event: Rebranding and Culture Shift
On September 14, Novo Nordisk announced it will conduct business under the single name Novo, while the legal entity remains Novo Nordisk A/S. The rollout includes a refreshed visual identity that retains the historic Apis bull logo, a new tagline “Lasting Health Starts Now,” and an internal culture program called “The Novo Way.” The four guiding principles are customer obsession, competitiveness, clarity, and care & integrity. The change is presented as the start of a new chapter aimed at regaining market share in the obesity-treatment segment.
Background & Context
Novo Nordisk, a pioneer of GLP-1 therapies, has faced pressure from rival Eli Lilly, whose dual GIP/GLP-1 products Zepbound and Mounjaro have eroded Novo’s dominance. In Q2 2026, Eli Lilly held roughly 61 % of the obesity-drug market, while Novo’s share stood at 38.8 % (IQVIA). The squeeze coincided with a steep decline in Novo’s share price, late-stage trial setbacks, and an approaching patent cliff for semaglutide, the active ingredient in Wegovy and Ozempic.
Data & Statistics
- Market share (Q2 2026): Novo 38.8 % vs. Eli Lilly 60.9 % (IQVIA).
- Oral Wegovy prescriptions: > 3 million in the United States by June 2026 (Novo press release).
- Global Wegovy oral uptake: ? 5 million prescriptions worldwide by late 2026.
- Semaglutide revenue contribution: ? 75 % of Novo’s 2026 revenue.
- Share-price performance:
- ? 15 % decline YTD (CNBC).
- 23 % decline over 12 months (Baystreet).
- Patent timeline: Semaglutide protection expires in Europe and the United States in the early-to-mid 2030s.
- Pipeline setbacks: Failed Phase 3 trials for the IL-6 inhibitor ziltivekimab and disappointing results for the combination drug CagriSema.
Official Statements & Responses
CEO Mike Doustdar, appointed in August 2025, emphasized the need for greater “focus, speed and impact” and reiterated the commitment to “lasting health starting right now.” The firm highlighted the oral Wegovy pill as a differentiator, noting its early market entry ahead of Eli Lilly’s oral GLP-1 candidate Foundayo, launched on April 1. Novo affirmed that its operating-profit guidance for 2026 remains unchanged despite the recent trial terminations.
Conflicting Reports & Gaps
Share-price decline figures differ across outlets, leaving the exact magnitude of investor sentiment ambiguous. While Novo projects flat to modestly negative revenue growth for 2026, precise forecasts for post-patent-expiry performance remain unspecified.
Timeline
- April 1: Eli Lilly launches oral weight-loss pill Foundayo.
- September 11: Morgan Stanley downgrades Novo Nordisk to “Underweight.”
- September 14: Novo Nordisk announces rebranding to “Novo” and unveils “The Novo Way.”
- September 15: Company-wide town-hall to discuss the “next chapter.”
- September 21: Capital Markets Day in London to detail the revised business strategy.
What's Next
Investors and analysts will look to the Capital Markets Day on September 21 for details on Novo’s growth plan, including how the firm intends to offset semaglutide’s impending patent loss and whether the oral Wegovy platform can sustain market leadership. The town-hall on September 15 is expected to provide internal perspectives on the cultural transformation and its impact on product development timelines.